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1. Introduction 
The mortality, hospitalization, and prevalence rates of heart failure (HF) are increasing, in 
spite of decrease in coronary artery and cerebrovascular disease mortality.[1] Importantly, 
heart failure with normal ejection fraction (HFNEF) currently accounts for more than 50% of 
all heart failure patients and as the prevalence of HFNEF in the heart failure population 
rises by 1% a year.[2]  
Approximately half of patients with a diagnosis of heart failure have a normal left 
ventricular (LV) ejection fraction (EF) without valve disease which is defined as diastolic 
heart failure (DHF), because it is attributed to LV diastolic dysfunction.[3] The prevalence of 
DHF increase even more dramatically with age more than HF with a reduced EF and is 
much more common in women than in men at any age. Studies examining prevalence of 
diastolic heart failure in hospitalized patients or in patients undergoing outpatient 
diagnostic screening and prospective community based studies have shown that the 
prevalence of diastolic heart failure approaches 50%.[4-6] Although HF patients with 
preserved systolic function has a slightly better prognosis than HF patients with abnormal 
systolic function, there is a fourfold higher mortality risk compared with subjects free of 
HF.[7] 
2. The mechanism of DHF  
Heart failure is a clinical syndrome characterized by symptoms and signs of increased tissue 
water and decreased tissue perfusion. Definition of the mechanisms that cause this clinical 
syndrome requires measurement of both systolic and diastolic function. When heart failure 
is accompanied by a predominant or isolated abnormality in diastolic function, this clinical 
syndrome is called diastolic heart failure. The pathophysiology is attributed to LV diastolic 
dysfunction, in which LV diastolic chamber size is normal or reduced despite elevated 
filling pressures resulting in decreased cardiac output. DHF occurs when the ventricular 
chamber is unable to accept an adequate volume of blood during diastole, because of a 
decrease in ventricular relaxation and/or an increase in ventricular stiffness,[3] and 
increased circulating blood volume is present. Hypertension, ischemia, aging and diabetes 
mellitus are the major risk factor of a decrease in ventricular relaxation and/or an increase 
in ventricular stiffness. Endocardial biopsies from HF patients without coronary artery 
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disease (CAD) showed structural and functional differences in cardiomyocytes from 
patients with diastolic HF compared to cardiomyocytes from patients with abnormal 
systolic ejection fraction.[8] Myocytes from patients with diastolic HF had increased 
diameter and higher myofibrillar density and developed greater passive force and had 
greater calcium sensitivity. Myocardial collagen volume fraction was equally elevated.  
2.1 Characteristics of medical examination  
Patients with DHF were shown to have similar pathophysiological characteristics, compared 
with HF patients with a reduced EF including reduced exercise capacity and impaired 
quality of life. The Framingham criteria for diagnosis of HF is the following. Major criteria 
are 1) paroxysmal nocturnal dyspnea or orthopnea, 2) jugular venous distention (or central 
venous pressure is more than 16 mmHg), 3) hearing rale or acute pulmonary edema, 4) 
cardiomegaly, 5) hepatojuglar reflex, and 6) response to diuretics (weight loss is more than 
4.5 kg per 5 days). Minor criteria are 1) ankle edema, 2) nocturnal cough, 3) exertional 
dyspnea, 4) pleural effusion, 5) vital capacity lower less than two thirds of normal condition, 
6) hepatomegaly, and 7) tachycardia (more than 120 beats/minute. With diastolic HF, fourth 
heart sounds may be present but third heart sounds are seldom present. Chest radiography 
will show pulmonary congestion during acute exacerbations and for some time following an 
episode, cardiomegaly will be present in systolic HF but may or may not be present in HF 
with preserved ejection fraction. When it is difficult with diagnosing HF, it is important to 
use echocardiography. [9,10] 
2.2 The diagnosis of DHF 
The diagnosis of heart failure with normal left ventricular (LV) ejection fraction (HFNEF) 
requires the following conditions to be satisfied: (1) signs or symptoms of heart failure; (2) 
normal or mildly abnormal systolic LV function; (3) evidence of diastolic LV dysfunction. 
Normal or mildly abnormal systolic LV function implies both an LVEF > 50% and an LV 
end-diastolic volume index (LVEDVI) < 97 mL/m2. Diagnostic evidence of diastolic LV 
dysfunction can be obtained invasively (LV end-diastolic pressure >16 mmHg or mean 
pulmonary capillary wedge pressure >12 mmHg) or non-invasively by tissue Doppler 
(TD) (E/E’ >15) with an echocardiography. If TD yields an E/E’ ratio suggestive of 
diastolic LV dysfunction ( 8 < E/E’ < 15 ), additional non-invasive investigations are 
required for diagnostic evidence of diastolic LV dysfunction. These can consist of blood 
flow Doppler of mitral valve or pulmonary veins, echocardiographic measures of LV mass 
index or left atrial volume index, electrocardiographic evidence of atrial fibrillation, or 
plasma levels of natriuretic peptides. If plasma BNP is more than 200 pg/mL, diagnostic 
evidence of diastolic LV dysfunction also requires additional non-invasive investigations 
(Fig. 1). 
LVEDVI: left ventricular end-diastolic volume index, mPCW: mean pulmonary capillary 
wedge pressure, LVEDP: left ventricular end-diastolic pressure, TD: tissue Doppler, E: early 
mitral valve flow velocity, E’: early TD lengthening velocity, BNP: brain natriuretic peptide, 
E/A: ratio of early (E) to late (A) mitral valve flow velocity, Dct: deceleration time, LVMI: 
left ventricular mass index; LAVI: left atrial volume index, Ard: duration of reverse 
pulmonary vein atrial systole flow, Ad: duration of mitral valve atrial wave flow. 
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Symptoms or signs of heart failure
Normal or mildly reduced left ventricular systolic function: LVEF > 50% and LVEDVI < 97 mL/m2
Evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic stiffness 
Invasive Heamodynamic measurements
mPCW > 12 mmHg
or
LVEDP > 15 mmHg
TD
15< E/E’ 8 < E/E’ <15
Heart failure of normal Ejection Fraction
Biomarkers
BNP > 200 pg/mL
TD
E/E’ > 8
EchocardiographyBiomarkers
BNP > 200 pg/mL E/A < 0.5 and Dct > 280 ms
in more than 50 years old persons
or
Ard-Ad > 30 ms
or
LAVI > 40 mL/m2
or
LVMI > 122 g/m2 (men), > 149 g/m2 (women)
or
Atrial fibrillation
 
 
 
 
Fig. 1. How to diagnose HFNEF: Diagnostic flow chart in a patient suspected of HFNEF. 
A similar strategy with focus on a high negative predictive value of successive 
investigations is proposed for the exclusion of HFNEF in patients with breathlessness and 
no signs of congestion. If a patient with breathlessness and no signs of fluid overload has a 
BNP of less than 100 pg/mL, any form of heart failure is virtually ruled out because of the 
high negative predictive value of the natriuretic peptides, and pulmonary disease becomes 
the most likely cause of breathlessness (Fig. 2). [11,12] 
As far as diastolic dysfunctuion, in decompensated patients with advanced systolic heart 
failure (LVEF≦30%, New York Heart Association class ˩ to ˪ symptoms), tissue Doppler-
derived with E/E’ ratio may not be as reliable in predicting intracardiac filling pressures, 
particularly in those with larger LV volumes, more impaired cardiac indices, and the 
presence of cardiac resynchronization therapy. [13] 
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Breathlessness, without signs of fluid overload
BNP > 100 pg/ml
Evidence of pulmonary disease
Yes
Echocardiography No
Yes
Consider pulmonary disease
Evidence of valvular or pericardial disease
No
LVEF > 50%
Consider valvular or pericardial disease
Yes
Yes
LVEDVI < 76 mL/m2
Consider HFREF
Yes
LAVI < 29 mL/m2
and no Atrial Fibrillation
Yes
Consider high output state
No
No
LVMI < 96 g/m2 (women),< 116 g/m2 (men)
TD Yes
E/E’ < 8
Consider HFNEF
No
No
No
Yes
No HFNEF
Consider coronary artery disease with
Deficient angina warning  
 
Fig. 2. How to exclude HFNEF: Diagnostic flow chart in a patient presenting with 
breathlessness and no signs of fluid overload.  
2.3 Echocardiography in diastolic heart failure 
2.3.1 Doppler echocardiographic assessment of diastolic function and filling 
pressures 
Comprehensive Doppler echocardiography is invaluable in the evaluation of HF patients as 
the 2.1. characteristics of medical examination section. Assessment of diastolic function 
begins with the transmitral flow velocity profile. Decreases in the ratio of early to late 
diastolic filling (E/A), increases in the deceleration time, increases in the isovolumic 
relaxation time, or increases in tissue Doppler imagings (E/E’) indicate impaired relaxation. 
However, in the presence of impaired relaxation, increases in filling pressure progressively 
modify the transmitral gradient and mitral inflow pattern. A comprehensive Doppler 
assessment must be used to determine diastolic function from filling pressures and tissue 
Doppler imagings. [12] Patients studied at various times during their presentation will 
display a spectrum of filling patterns, including abnormal relaxation and psuedonormal or 
restrictive patterns. Such a spectrum has also been reported in patients with HF with a 
depressed EF and reflects the potent effect of filling pressures and blood pressure and their 
interaction with underlying diastolic dysfunction on the Doppler patterns. Thus, depending 
on their level of compensation and their filling pressures and whether they have exertional 
or rest symptoms, patients with HF preserved EF may display any of the filling patterns.[14]  
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Fig. 3. Normal pattern in LV inflow: Panel A shows long axis view. Panel B shows 4 
chamber view. Panel C shows LV inflow. Panel D shows tissue Doppler imaging. 
A B
C D
 
Fig. 4. Abnormal relaxation pattern in LV inflow: Panel A shows long axis view. Panel B 
shows 4 chamber view. Panel C shows LV inflow. Panel D shows tissue Doppler imaging. 
2.3.2 Left ventricle in diastolic heart failure  
Most patients with HF preserved EF have normal chamber dimensions, although a small 
subset may have variable degrees of LV enlargement. 
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Although HF preserved EF has been thought to occur primarily inpatients with LVH, 
studies that have carefully quantified LV mass report that echocardiographic criteria for 
LVH are met in less than 50% of patients. [15-18]  
2.3.3 Left atrium in diastolic heart failure 
Increases in the left atrial dimension or volume are commonly present in patients with HF 
preserved EF. [19-21]  
2.3.4 Pulmonary hypertension in diastolic heart failure 
Just as chronic pulmonary venous hypertension leads to pulmonary arterial hypertension in 
HF with reduced EF, the same can occur in HF preserved EF, and an elevated tricuspid 
regurgitant velocity indicative of pulmonary hypertension is extremely common in HF 
preserved EF.[19, 22]  
2.3.5 Other echocardiographic findings in diastolic heart failure 
Regional wall motion abnormalities with preserved EF and right ventricular dilatation, 
either from ischemic disease or secondary to chronic pressure overload from chronic 
pulmonary venous hypertension, can also be present at echocardiography in patients with 
HF preserved EF. Additional negative findings at echocardiography include the absence of 
valvular disease, pericardial tamponade, pericardial constriction, the presence of congenital 
heart diseases such as atrial septal defect, other more extensive structural abnormalities are 
important enough to cause the HF symptoms. 
2.4 The treatment of DHF 
Almost randomized, double-blind studies of therapy for HF are studies of systolic 
dysfunction. Guidelines for the management of patients with chronic HF have been 
published by several organizations. The management of patients with DHF is not different 
from that of HF patients with a reduced EF. They include daily monitoring of weight, 
attention to patient education, and close medical follow-up. The role of cardiac 
rehabilitation in patients with DHF has also been explored.[23]  
The treatment of diastolic heart failure can be demonstrated the following 3 strategies. First, 
treatment should target symptom reduction by decreasing pulmonary venous pressure at 
rest and during exertion. Second, treatment should target the pathological disease that 
caused the diastolic heart failure. For example, coronary artery disease, hypertensive heart 
disease and diabetes mellitus provide relatively specific therapeutic targets, such as 
lowering of blood pressure, induction of hypertrophy regression, blood sugar control and 
treatment of ischemia by increasing myocardial blood flow and reducing myocardial oxygen 
demand. Third, treatment should target the underlying mechanisms that are altered by the 
disease processes.  
Diuretics are advised for therapy of diastolic HF in the ACC/AHA Guidelines for 
Evaluation and Management of Heart Failure. The use of diuretics may improve 
breathlessness in patients with diastolic HF, because circulating blood volume is a major 
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determinant of ventricular filling pressure. In spite of chronic data are lacking on nitrates, 
they are effective on the diastolic HF in the acute phase, because of deceasing central blood 
volume by vasodilating. In spite of chronic data are also lacking on human atrial natriuretic 
peptides, they are effective on the diastolic HF in the acute phase, because of deceasing 
central blood volume by natriuretic and vasodilating effect. Digoxin was reported to yield 
symptomatic improvement and decreased hospitalizations without mortality benefit in the 
DIG study in patients with DHF.[24]  
We treat with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs) and aldosterone antagonists in the chronic systolic heart failure patients, 
because the rennin-angiotensin- aldosterone system (RAAS) plays the pivotal roles on the 
left ventricular remodeling in HF patients.[25] Recent studies of HF patients with preserved 
LV function suggest that ACE inhibitors or ARBs may improve functional class, exercise 
duration, ejection fraction, diastolic filling and LV hypertrophy. In the large randomized 
trial of perindopril (an ACE inhibitor) for patients older than 70 years with chronic HF and 
normal or near-normal EF, event rates were lower than anticipated. Some trends toward 
benefit, primarily driven by reduction in HF-related hospitalizations, were observed at 1 
year (PEP-CHF trial).[26] In the CHARM-Preserved Trial, [27] HF patients with an EF higher 
than 40% were randomized to candesartan ( an angiotensin receptor antagonist ) or placebo 
in addition to standard therapy. Fewer patients in the candesartan group than in the placebo 
group reached the primary endpoint of cardiovascular death or HF hospitalization, a 
finding that reached statistical significance only after adjustment for nonsignificant 
differences in baseline characteristics. Then, irbesartan (an ARB) did not improve the 
outcomes of DHF patients (I-PRESERVE).[28] Although candesartan and irbesartan are 
angiotensin receptor blockers, the results of the trials are different. These pleiotropic effects 
may be different. The trial of aldosterone antagonists for DHF patients is going on in DHF 
patients (TOPCAT trial). Beta blocker has been shown to improve morbidity with diastolic 
and systolic HF. [29,30] Although calcium channel antagonists can improve measures of 
diastolic function during short-term use, definitive data with chronic administration for 
diastolic HF are not available. Recent reports show statins reduce the number of 
cardiovascular hospitalizations in patients with systolic heart failure, although they did not 
reduce the primary outcome which is the composite of death from cardiovascular causes, 
non fatal myocardial infarction and nonfatal stroke.[31,32] A few trials of statins have 
shown to improve the mortality in patients with DHF [33]. Further investigations are 
needed. 
3. Conclusions 
Heart failure with normal left ventricular ejection fraction (HFNEF) currently accounts for 
more than 50% of all heart failure patients. The updated strategies for the diagnosis and 
exclusion of HFNEF are useful not only for individual patient management but also for 
patient recruitment in future clinical trials exploring therapies for HFNEF. 
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